Surrogate antibodies and methods of preparation and use thereof

• US 20040018508A1
• Filed: 02/19/2003
• Published: 01/29/2004
• Est. Priority Date: 02/19/2002
• Status: Abandoned Application

• Current Assignee: Syntherica Corporation
• Original Assignee: Syntherica Corporation
• Inventors: Friedman, Stephen B.
• Application Number:
  US10/370,052
• Publication Number:
  US 20040018508A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/283 against Fc-receptors, e.g. CD16, CD32, CD64 CD23 C07K16/2851
• CPC Class Codes: C07K 16/4283 : against an allotypic or isotypic determinant on Ig
• CPC Class Codes: C07K 16/44 : against material not provided for elsewhere , e.g. haptens, metals, DNA, RNA, amino acids
• CPC Class Codes: C07K 2317/31 : multispecific

Abstract

A process is described for producing surrogate antibody molecules that mimic the structure, stability, and binding characteristics of a natural antibody. Surrogate antibody structure, composition of surrogate antibody libraries, methods of surrogate antibody preparation, and surrogate antibody applications are disclosed. Also disclosed are methods of surrogate antibody structural stabilization and resistance to nucleases. The surrogate antibodies comprise a specificity strand and a stabilization strand. The specificity strand comprises a nucleic acid sequence having a specificity region flanked by a first constant region and a second constant region. The stabilization strand comprises a first stabilization region that interacts with the first constant region and a second stabilization region that interacts with the second constant region. In further embodiments, the stabilization strand and the specificity strand comprise distinct molecules. In other embodiments, the surrogate antibody molecules may comprise polyoligonucleotides that have at least one nucleotide sequence that forms a loop with specific ligand-binding properties. Surrogate antibody libraries containing a large population of random binding molecules are pre-assembled and used in a process that captures and amplifies those molecules having prerequisite binding characteristics. The amplified surrogate antibody molecule produced by the process has identical structure and binding characteristics to the parent molecule captured from the initially assembled library. Surrogate antibody molecules contain binding loop(s) that are formed and stabilized by the hybridization of at least two adjacent and juxtaposed strands, one strand having a greater number of nucleotides than the other. The preparation of a polyclonal surrogate antibody reagent proceeds through phases of capture/enrichment and amplification, specificity enhancement, and affinity enhancement. Depending upon the intended application, polyclonal surrogate antibody reagents can be processed to monoclonality. These molecules expand upon the binding characteristics of natural immunoglobulins, and do not require animals, animal facilities, cell culture or the stimulation of an immune response, in their development. They can be used as an effective replacement for natural antibody molecules, and therefore can be used in testing methods like immunoassay, as therapeutic agents, for specific labeling, and for research purposes. Targets ligands compatible with the development of surrogate antibodies include compounds, organisms, and cells that when complexed to a surrogate antibody in solution attain characteristics that can be physically or chemically differentiated from uncomplexed surrogate antibody.

Claims

1. An isolated molecule comprising a specificity strand and a stabilization strand,

said specificity strand comprising a nucleic acid sequence having a specificity region flanked by a first constant region and a second constant region;

said stabilization strand comprises a first stabilization domain that interacts with said first constant region and a second stabilization domain that interacts with said second constant region; and

,

said stabilization strand and said specificity strand comprise distinct molecules.

2. The isolated molecule of claim 1, wherein said stabilization strand further comprises a first spacer domain between said first stabilization domain and said second stabilization domain.

3. The isolated molecule of claim 1, wherein said stabilization strand comprises an amino acid sequence.

4. The isolated molecule of claim 1, wherein said nucleic acid sequence comprises a deoxribonucleic acid sequence or a ribonucleic acid sequence.

5. The isolated molecule of claim 1, wherein said molecule further comprises at least one functional moiety.

6. The isolated molecule of claim 1, wherein said specificity region binds a ligand.

7. The isolated molecule of claim 1, wherein said stabilization strand comprises a second nucleic acid sequence.

8. The isolated molecule of claim 7, wherein at least one of said nucleic acid sequence or said second nucleic acid sequence comprises a deoxyribonucleic acid sequence or a ribonucleic acid sequence.

9. The isolated molecule of claim 7, wherein the second nucleic acid sequence comprising said stabilization strand is at least 8 nucleotides.

10. The isolated molecule of claim 7, wherein said specificity strand comprises at least 10 nucleotides.

11. The isolated molecule of claim 7, wherein said molecule binds a ligand.

12. The isolated molecule of claim 11, wherein said ligand comprises a polypeptide, a nucleotide, a chemical compound, a mucopolysacharide, a cell, an organism, a bacteria, a virus, a lipid, an inorganic molecule, an organic molecule or a PCB.

13. The isolated molecule of claim 12, wherein said polypeptide is a receptor.

14. The isolated molecule of claim 7, wherein said molecule acts as a ligand.

15. The isolated molecule of claim 7, wherein said molecule further comprises at least one functional moiety.

16. The isolated molecule of claim 15, wherein said functional moiety comprises a reporter molecule, an affinity type molecule, a linking molecule, or an enzyme.

17. The isolated molecule of claim 15, wherein said functional moiety is an organic molecule or an inorganic molecule.

18. The isolated molecule of claim 15, wherein said functional moiety is a therapeutic agent.

19. The isolated molecule of claim 18, wherein said therapeutic agent is an anti-microbial agent having anti-microbial activity.

20. The isolated molecule of claim 19, wherein said anti-microbial activity comprises anti-bacterial activity, anti-viral activity, or anti-fungal activity.

21. The isolated molecule of claim 15, wherein said functional moiety comprises at least one modified nucleotide.

22. The isolated molecule of claim 15, wherein said functional moiety is located in said specificity region.

23. The isolated molecule of claim 22, wherein said functional moiety introduces hydrophobic binding capabilities into said specificity region.

24. The isolated molecule of claim 15, wherein said functional moiety comprise a modified nucleotide having a modification at the 2′

position of the nucleotide sugar or phosphate molecule.

25. The isolated molecule of claim 15, wherein said functional moiety increases resistance to nuclease degradation.

26. The isolated molecule of claim 15, wherein said functional moiety is located in said stabilization strand.

27. The isolated molecule of claim 26, wherein said functional moiety comprises a non-amplifiable moiety that increases resistance to polymerase activity in a PCR reaction.

28. The isolated molecule of claim 1, wherein

said specificity strand further comprises a second specificity region flanked by said second constant region and a third constant region;

and,

said stabilization strand further comprises a third stabilization domain that interacts with said third constant region.

29. The isolated molecule of claim 28, wherein said stabilization strand further comprises a first spacer region between said first stabilization and said second stabilization domain and a second spacer region between said second stabilization domain and said third stabilization domain.

30. The isolated molecule of claim 28, wherein said stabilization strand comprises a nucleic acid sequence.

31. The isolated molecule of claim 28, wherein said stabilization strand comprises an amino acid sequence.

32. A composition comprising a population of molecules of claim 1.

33. A library of isolated molecules comprising:

a population of molecules comprising a specificity strand and a stabilization strand, said specificity strand comprising a nucleic acid sequence having a specificity region flanked by a first constant region and a second constant region; and

, said stabilization strand comprises a first stabilization domain that interacts with said first constant region and a second stabilization domain that interacts with said second constant region; and

,

wherein each of the first constant region of said specificity strands in said population are identical;

each of the second constant region of said specificity strands in said population are identical; and

, each of the specificity region of said specificity strands in said population are randomized; and

,

wherein each of the stabilization strands in said population are identical.

34. The library of claim 33, wherein said stabilization strand and said specificity strand comprise distinct molecules.

35. A library of isolated molecules produced by

a) providing a population of specificity strands wherein

i) each of said specificity strand in said population comprises a nucleic acid sequence having a specificity region flanked by a first constant region and a second constant region;

ii) each of the first constant region of said specificity strands in said population are identical;

iii) each of the second constant region of said specificity strands in said population are identical; and

,

iv) each of the specificity region of said specificity strands in said population are randomized; and

,

b) contacting said population of specificity strands with a stabilization strand;

wherein said stabilization strand comprises a first stabilization domain that interacts with said first constant region and a second stabilization domain that interacts with said second constant region; and

,

said contacting occurs under conditions that allow for said first stabilization domain to interact with said first constant region and said second stabilization domain to interacts with said second constant region.

36. The library of claim 35, wherein said stabilization strand and said specificity strand comprise distinct molecules.

37. A method for generating a surrogate antibody library comprising:

a) providing a population of specificity strands wherein

i) each of said specificity strand in said population comprises a nucleic acid sequence having a specificity region flanked by a first constant region and a second constant region;

ii) each of the first constant region of said specificity strands in said population are identical;

iii) each of the second constant region of said specificity strands in said population are identical; and

,

iv) each of the specificity regions of said specificity strands in said population are randomized; and

,

b) contacting said population of specificity strands with a stabilization strand;

wherein said stabilization strand comprises a first stabilization domain that interacts with said first constant region and a second stabilization domain that interacts with said second constant region; and

,

said contacting occurs under conditions that allow for said first stabilization domain to interact with said first constant region and said second stabilization domain to interacts with said second constant region.

38. The method of claim 37, wherein said stabilization strand and said specificity strand comprise distinct molecules.

39. A method for capturing a surrogate antibody comprising:

a) contacting a ligand with a population of surrogate antibody molecules under conditions that permit formation of a population of ligand-bound surrogate antibody complexes, wherein each of the surrogate antibody molecules of the surrogate antibody population comprises a specificity strand and a stabilization strand,

said specificity strand comprising a nucleic acid sequence having a specificity region flanked by a first constant region and a second constant region;

said stabilization strand comprises a first stabilization domain that interacts with said first constant region and a second stabilization domain that interacts with said second constant region;

b) partitioning said ligand and said population of surrogate antibody molecules from said population of ligand-bound surrogate antibody complexes; and

,

c) amplifying the specificity strand of said population of ligand-bound surrogate antibody complexes.

40. The method of claim 39, wherein said population comprises a library of surrogate antibody molecules.

41. The method of claim 39, wherein said stabilization strand and said specificity strand comprise distinct molecules.

42. The method of claim 41, wherein said population comprises a selected population of surrogate antibodies.

43. The method of claim 39, wherein said method further comprises contacting said population of specificity strands of step (c) with a stabilization strand under conditions that allow for said first stabilization domain to interact with said first constant region and said second stabilization domain to interact with said second constant region.

44. The method of claim 39, wherein said method further comprises isolating a cloned specificity strand said isolating comprising cloning at least one specificity strand of the amplified population of specificity strands of step (c).

45. The method of claim 44, wherein said method further comprises contacting said cloned specificity strand with the stabilization strand under conditions that allow for said first stabilization domain to interact with said first constant region and said second stabilization domain to interact with said second constant region.

46. The method of claim 39, wherein partitioning comprises filtering said ligand, said population of surrogate antibody molecules, and said population of ligand-bound surrogate antibody complexes through a membrane having a porosity that retains the ligand-bound surrogate antibody complex in the retentate and allows unbound surrogate antibodies to pass into the filtrate.

47. A method of detecting a ligand comprising

a) contacting said ligand with a surrogate antibody molecule under conditions that permit formation of a population of ligand-bound surrogate antibody complexes, wherein said surrogate antibody molecule comprises a specificity strand and a stabilization strand,

said specificity strand comprising a nucleic acid sequence having a variable region flanked by a first constant region and a second constant region;

said stabilization strand comprises a first stabilization domain that interacts with said first constant region and a second stabilization domain that interacts with said second constant region; and

,

b) detecting said ligand.